Assessment of The Impact of Apremilast on Levels of IL-17, IL-23, and Lipids in Obese Psoriatic Patient
Background: Psoriasis is an immune-mediated inflammatory disease with unknown aetiology that may be associated with the defect in proliferation and differentiation of the keratinocytes related to inflammatory cell infiltration. According to published reports, it is universal in occurrence; its prev...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
College of Medicine University of Baghdad
2024-12-01
|
| Series: | مجلة كلية الطب |
| Subjects: | |
| Online Access: | https://iqjmc.uobaghdad.edu.iq/index.php/19JFacMedBaghdad36/article/view/2260 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832594676323975168 |
|---|---|
| author | Haitham M. Saad Adil A. Noaimi Halla Gh. Mahmood |
| author_facet | Haitham M. Saad Adil A. Noaimi Halla Gh. Mahmood |
| author_sort | Haitham M. Saad |
| collection | DOAJ |
| description |
Background: Psoriasis is an immune-mediated inflammatory disease with unknown aetiology that may be associated with the defect in proliferation and differentiation of the keratinocytes related to inflammatory cell infiltration. According to published reports, it is universal in occurrence; its prevalence in different populations varies from 0.1% to 11.8%. Receiving Apremilast resulted in a strong reduction in interleukin 17 and interleukin 23, as well as reduced expression of other inflammatory cytokines and improvement of psoriatic lesions.
Objectives: This study aimed to assess the impact of Apremilast on levels of IL-17, IL-23, and lipids in obese psoriatic patients.
Methods: Thirty obese patients with psoriasis were included in this prospective interventional study to measure serum levels of lipid profile, IL-17, and IL-23, before and after receiving Apremilast treatment. A t-test was used to compare between means.
Results: The mean age of the participants was 38 years. The most common age group was 30–40 years. The levels of IL-17 before the administration of Apremilast were 225.55 ± 7.70 pg/mL. After six months of treatment with Apremilast, a statistically significant reduction was seen, with the value decreasing to 183.41 ±2.33 pg/ml. IL-22 levels before the administration of Apremilast were measured to be 76.42 ± 4.03 pg/mL. After six months of treatment with Apremilast, these levels exhibited a non-significant decrease to 67.15 ± 5.40 pg/ml. Modest alterations were noted in the lipid profile.
Conclusion: The use of Apremilast is effective in decreasing IL-17 levels, which have pro-inflammatory effects; this leads to improvement in psoriatic lesions. Moreover, receiving Apremilast in obese psoriatic individuals led to a reduction in TG levels and an elevation in HDL-C levels. Additionally, a rise in TC levels and LDL-C was seen.
|
| format | Article |
| id | doaj-art-280f80b3b67e46d7b8c0e76ce3623eab |
| institution | Kabale University |
| issn | 0041-9419 2410-8057 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | College of Medicine University of Baghdad |
| record_format | Article |
| series | مجلة كلية الطب |
| spelling | doaj-art-280f80b3b67e46d7b8c0e76ce3623eab2025-01-19T12:24:10ZengCollege of Medicine University of Baghdadمجلة كلية الطب0041-94192410-80572024-12-0166410.32007/jfacmedbaghdad.6642260Assessment of The Impact of Apremilast on Levels of IL-17, IL-23, and Lipids in Obese Psoriatic PatientHaitham M. Saad0https://orcid.org/0009-0003-3135-0281Adil A. Noaimi1https://orcid.org/0000-0002-2436-7988Halla Gh. Mahmood2https://orcid.org/0000-0002-7248-4409Al-Anbar Health Directorate, Ministry of Health, Anbar, Iraq.Department of Internal Medicine, College of Medicine, University of Baghdad, Baghdad, Iraq.Department of Clinical Biochemistry, College of Medicine, University of Baghdad, Baghdad, Iraq. Background: Psoriasis is an immune-mediated inflammatory disease with unknown aetiology that may be associated with the defect in proliferation and differentiation of the keratinocytes related to inflammatory cell infiltration. According to published reports, it is universal in occurrence; its prevalence in different populations varies from 0.1% to 11.8%. Receiving Apremilast resulted in a strong reduction in interleukin 17 and interleukin 23, as well as reduced expression of other inflammatory cytokines and improvement of psoriatic lesions. Objectives: This study aimed to assess the impact of Apremilast on levels of IL-17, IL-23, and lipids in obese psoriatic patients. Methods: Thirty obese patients with psoriasis were included in this prospective interventional study to measure serum levels of lipid profile, IL-17, and IL-23, before and after receiving Apremilast treatment. A t-test was used to compare between means. Results: The mean age of the participants was 38 years. The most common age group was 30–40 years. The levels of IL-17 before the administration of Apremilast were 225.55 ± 7.70 pg/mL. After six months of treatment with Apremilast, a statistically significant reduction was seen, with the value decreasing to 183.41 ±2.33 pg/ml. IL-22 levels before the administration of Apremilast were measured to be 76.42 ± 4.03 pg/mL. After six months of treatment with Apremilast, these levels exhibited a non-significant decrease to 67.15 ± 5.40 pg/ml. Modest alterations were noted in the lipid profile. Conclusion: The use of Apremilast is effective in decreasing IL-17 levels, which have pro-inflammatory effects; this leads to improvement in psoriatic lesions. Moreover, receiving Apremilast in obese psoriatic individuals led to a reduction in TG levels and an elevation in HDL-C levels. Additionally, a rise in TC levels and LDL-C was seen. https://iqjmc.uobaghdad.edu.iq/index.php/19JFacMedBaghdad36/article/view/2260ApremilastIL-17IL-23 ObesePsoriasis |
| spellingShingle | Haitham M. Saad Adil A. Noaimi Halla Gh. Mahmood Assessment of The Impact of Apremilast on Levels of IL-17, IL-23, and Lipids in Obese Psoriatic Patient مجلة كلية الطب Apremilast IL-17 IL-23 Obese Psoriasis |
| title | Assessment of The Impact of Apremilast on Levels of IL-17, IL-23, and Lipids in Obese Psoriatic Patient |
| title_full | Assessment of The Impact of Apremilast on Levels of IL-17, IL-23, and Lipids in Obese Psoriatic Patient |
| title_fullStr | Assessment of The Impact of Apremilast on Levels of IL-17, IL-23, and Lipids in Obese Psoriatic Patient |
| title_full_unstemmed | Assessment of The Impact of Apremilast on Levels of IL-17, IL-23, and Lipids in Obese Psoriatic Patient |
| title_short | Assessment of The Impact of Apremilast on Levels of IL-17, IL-23, and Lipids in Obese Psoriatic Patient |
| title_sort | assessment of the impact of apremilast on levels of il 17 il 23 and lipids in obese psoriatic patient |
| topic | Apremilast IL-17 IL-23 Obese Psoriasis |
| url | https://iqjmc.uobaghdad.edu.iq/index.php/19JFacMedBaghdad36/article/view/2260 |
| work_keys_str_mv | AT haithammsaad assessmentoftheimpactofapremilastonlevelsofil17il23andlipidsinobesepsoriaticpatient AT adilanoaimi assessmentoftheimpactofapremilastonlevelsofil17il23andlipidsinobesepsoriaticpatient AT hallaghmahmood assessmentoftheimpactofapremilastonlevelsofil17il23andlipidsinobesepsoriaticpatient |